Tags

Type your tag names separated by a space and hit enter

Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention.
Am J Cardiovasc Drugs. 2006; 6(6):373-81.AJ

Abstract

Congestive heart failure (CHF) is a major public health problem that results in tremendous economic burden. Diastolic heart failure (DHF) forms an important subset with increasing incidence and prevalence. There are widely variable estimates of the prevalence, ranging from 13% to 74% of all CHF presentations, and this is predominantly a result of a lack of uniform criteria for establishing a diagnosis. New developments in management of DHF have lagged behind those for systolic heart failure (SHF), for which numerous new therapeutic and device strategies have been instituted. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathophysiology of both SHF as well as DHF. The beneficial role of ACE inhibitors as well as aldosterone antagonists in SHF has been well established. Because of its unique role of the RAAS in establishing fibrosis at a molecular level, RAAS blockade provides an opportunity to expand the therapeutic options for DHF. Thus far, in patients with primary DHF only the angiotensin receptor type 1 antagonist candesartan has been reported to decrease morbidity and probably mortality. Large, ongoing randomized trials including TOPCAT (Trial of Aldosterone Antagonist Therapy in Adults with Preserved Ejection Fraction Congestive Heart) and the I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function) are currently underway to establish the role of aldosterone antagonists in patients with DHF.

Authors+Show Affiliations

Department of Cardiology, Wayne State University School of Medicine, Detroit, MI 48201, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Review

Language

eng

PubMed ID

17192127

Citation

Bernal, Juan, et al. "Role of the Renin-angiotensin-aldosterone System in Diastolic Heart Failure: Potential for Pharmacologic Intervention." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 6, no. 6, 2006, pp. 373-81.
Bernal J, Pitta SR, Thatai D. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am J Cardiovasc Drugs. 2006;6(6):373-81.
Bernal, J., Pitta, S. R., & Thatai, D. (2006). Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, 6(6), 373-81.
Bernal J, Pitta SR, Thatai D. Role of the Renin-angiotensin-aldosterone System in Diastolic Heart Failure: Potential for Pharmacologic Intervention. Am J Cardiovasc Drugs. 2006;6(6):373-81. PubMed PMID: 17192127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. AU - Bernal,Juan, AU - Pitta,Sridevi R, AU - Thatai,Deepak, PY - 2006/12/29/pubmed PY - 2007/3/30/medline PY - 2006/12/29/entrez SP - 373 EP - 81 JF - American journal of cardiovascular drugs : drugs, devices, and other interventions JO - Am J Cardiovasc Drugs VL - 6 IS - 6 N2 - Congestive heart failure (CHF) is a major public health problem that results in tremendous economic burden. Diastolic heart failure (DHF) forms an important subset with increasing incidence and prevalence. There are widely variable estimates of the prevalence, ranging from 13% to 74% of all CHF presentations, and this is predominantly a result of a lack of uniform criteria for establishing a diagnosis. New developments in management of DHF have lagged behind those for systolic heart failure (SHF), for which numerous new therapeutic and device strategies have been instituted. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathophysiology of both SHF as well as DHF. The beneficial role of ACE inhibitors as well as aldosterone antagonists in SHF has been well established. Because of its unique role of the RAAS in establishing fibrosis at a molecular level, RAAS blockade provides an opportunity to expand the therapeutic options for DHF. Thus far, in patients with primary DHF only the angiotensin receptor type 1 antagonist candesartan has been reported to decrease morbidity and probably mortality. Large, ongoing randomized trials including TOPCAT (Trial of Aldosterone Antagonist Therapy in Adults with Preserved Ejection Fraction Congestive Heart) and the I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function) are currently underway to establish the role of aldosterone antagonists in patients with DHF. SN - 1175-3277 UR - https://www.unboundmedicine.com/medline/citation/17192127/Role_of_the_renin_angiotensin_aldosterone_system_in_diastolic_heart_failure:_potential_for_pharmacologic_intervention_ L2 - https://dx.doi.org/10.2165/00129784-200606060-00004 DB - PRIME DP - Unbound Medicine ER -